tetano
Editor, Senior Moderator
Curr Med Chem. 2017 Sep 20. doi: 10.2174/0929867324666170920165926. [Epub ahead of print]
[h=1]Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral.[/h] Han J[SUP]1[/SUP], Perez J[SUP]1[/SUP], Schafer A[SUP]2[/SUP], Cheng H[SUP]2[/SUP], Peet N[SUP]3[/SUP], Rong L[SUP]2[/SUP], Manicassamy B[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza viruses cause severe upper respiratory illness in young children and the elderly during seasonal epidemics. Influenza viruses also have the potential to cause pandemics with significant loss of life in all age groups. Although vaccination is one of the most effective methods to protect against seasonal epidemics, seasonal vaccines afford lowered protection against emerging variant strains and no protection against novel strains. Moreover, the efficacy of influenza virus vaccines is considerably lower in the elderly population. Small molecule therapeutics are a critical part of our antiviral strategies to control influenza virus epidemics and pandemics as well as to ameliorate disease symptoms in the elderly and in immunocompromised individuals. In this review, we will discuss the status of existing anti-influenza drugs, the mechanisms of antiviral resistance, and the novel antiviral drugs currently under development to target influenza viruses.
Copyright? Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
[h=4]KEYWORDS:[/h] Influenza virus; antiviral drugs; antiviral resistance.
PMID: 28933281 DOI: 10.2174/0929867324666170920165926
[h=1]Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral.[/h] Han J[SUP]1[/SUP], Perez J[SUP]1[/SUP], Schafer A[SUP]2[/SUP], Cheng H[SUP]2[/SUP], Peet N[SUP]3[/SUP], Rong L[SUP]2[/SUP], Manicassamy B[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza viruses cause severe upper respiratory illness in young children and the elderly during seasonal epidemics. Influenza viruses also have the potential to cause pandemics with significant loss of life in all age groups. Although vaccination is one of the most effective methods to protect against seasonal epidemics, seasonal vaccines afford lowered protection against emerging variant strains and no protection against novel strains. Moreover, the efficacy of influenza virus vaccines is considerably lower in the elderly population. Small molecule therapeutics are a critical part of our antiviral strategies to control influenza virus epidemics and pandemics as well as to ameliorate disease symptoms in the elderly and in immunocompromised individuals. In this review, we will discuss the status of existing anti-influenza drugs, the mechanisms of antiviral resistance, and the novel antiviral drugs currently under development to target influenza viruses.
Copyright? Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
[h=4]KEYWORDS:[/h] Influenza virus; antiviral drugs; antiviral resistance.
PMID: 28933281 DOI: 10.2174/0929867324666170920165926